|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2008-4-16
|
|
pubmed:abstractText |
The Fanconi gene family has a role in DNA repair and inactivation of FANCF has been proposed as a mechanism of sensitisation to platinum chemotherapy. This study sought to confirm this hypothesis in cell lines and a large series of ovarian cancer samples. Promoter methylation was assessed by methylation-sensitive polymerase chain reaction of FANCF in nine ovarian cancer cell lines and 74 ovarian cancer samples taken from patients entered on a trial of cisplatin-based chemotherapy. This study confirmed methylation-dependent silencing of FANCF in one out of nine ovarian cancer cell lines. Methylation of FANCF was demonstrated in 13.2% of 53 evaluable ovarian tumour samples. Progression-free survival gave an HR of 3.63 (95% CI: 1.54-8.54, P=0.0016) in favour of the unmethylated cases. There was no association with overall survival. This study does not support methylation-dependent silencing of FANCF as a mechanism of sensitisation to platinum-based chemotherapy in ovarian cancer.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414472-12509764,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414472-12692539,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414472-12724761,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414472-14647419,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414472-14656271,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414472-15126331,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414472-15149548,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414472-15240532,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414472-16204069,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414472-16418574,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414472-2374399
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
22
|
|
pubmed:volume |
98
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1452-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18414472-Cell Line, Tumor,
pubmed-meshheading:18414472-Cisplatin,
pubmed-meshheading:18414472-CpG Islands,
pubmed-meshheading:18414472-DNA Methylation,
pubmed-meshheading:18414472-Fanconi Anemia Complementation Group F Protein,
pubmed-meshheading:18414472-Female,
pubmed-meshheading:18414472-Humans,
pubmed-meshheading:18414472-Neoplasms, Glandular and Epithelial,
pubmed-meshheading:18414472-Ovarian Neoplasms,
pubmed-meshheading:18414472-Promoter Regions, Genetic
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
|
|
pubmed:affiliation |
Division of Surgery and Oncology, School of Cancer Studies, University of Liverpool, Liverpool, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
